Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RKTO, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Xuebijing | Pulmonary Disease, Chronic Obstructive | Phase 4 · NCT02937974 | Unknown |
| Mozafancogene Autotemcel | Fanconi Anemia Complementation Group A | Phase 2 · NCT04248439 | Active not recruiting |
| RP-L201 | Leukocyte Adhesion Defect - Type I | Phase 1/2 · NCT03812263 | Completed |
| RP-L301 | Pyruvate Kinase Deficiency | Phase 2 · NCT06422351 | Suspended |
| Genetically Engineered Hematopoietic Stem… | Fanconi Anemia | Phase 1 · NCT01331018 | Terminated |
| Methylprednisolone | Fanconi Anemia | Phase 1 · NCT01331018 | Terminated |
| RP-A501 | Danon Disease | Phase 1 · NCT03882437 | Completed |
| Autologous CD34+-enriched HSPCs Transduced with… | Infantile Malignant Osteopetrosis | Phase 1 · NCT04525352 | Terminated |
Also used in these trials (approved or third-party drugs, not RKTO's own candidates): Filgrastim, Plerixafor, Prednisone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RKTO holds $6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 75 · High
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RKTO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Robb Knie CEO and President, Director · +1.11M options |
Insider | 547,387 | 2.20% | 2025-08-27 |
Share count 24,897,581 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RKTO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →